Last updated: May 13, 2026
Homatropine Methylbromide and Hydrocodone Bitartrate API and Finished-Dose Suppliers: Who Manufactures the Actives and Combination Products?
What companies supply homatropine methylbromide API for pharmaceutical manufacturing?
Homatropine methylbromide is an anticholinergic component used in combination products (historically often paired with analgesic opioids in certain markets). The supply chain typically splits into (1) chemical API manufacturers and (2) finished-dose manufacturers who source the API.
Typical supplier categories
- API chemical manufacturers (route synthesis of homatropine methylbromide).
- Contract manufacturers / repackagers (API supply to finished-dose sites, often via distribution).
- Finished-dose generic and brand manufacturers (who source API and produce the combination product under local registrations).
API sourcing footprint
- Homatropine methylbromide is a niche API. Supplier lists are fragmented across regional catalogs and distributor inventories. For due diligence, procurement teams usually validate via:
- DMF/ASMF holder alignment to intended jurisdiction submissions
- supplier audit status for API GMP
- COA traceability and impurity profile consistency
- controlled-substance compliance where the combination includes hydrocodone
What companies supply hydrocodone bitartrate API for pharmaceutical manufacturing?
Hydrocodone bitartrate is a controlled opioid API. Supplier qualification is constrained by:
- regulatory licensing for opioid manufacture and handling
- diversion controls
- quota and inventory reporting systems
- customer-by-customer compliance reviews
Typical sourcing footprint
- Major opioid-active pharma ingredient manufacturers with long-running controlled-substance supply programs.
- Regional API makers that support bulk opioid supply to finished-dose manufacturers.
- Distributors and toll-manufacturing arrangements tied to specific controlled-substance registrations.
Procurement reality for hydrocodone
- Finished-dose manufacturers frequently lock API supply through long-term framework agreements due to quota variability and compliance overhead.
Which suppliers provide the combination product containing homatropine methylbromide and hydrocodone bitartrate?
Finished-dose combination availability is market- and jurisdiction-dependent. Combination products with hydrocodone plus anticholinergic components are often used for cough/analgesic indications in specific regulatory contexts, but presence varies sharply by country, sponsor history, and scheduling rules.
How combination supply is commonly structured
- Finished-dose manufacturers:
- either own the API via in-house manufacture (less common for this combination)
- or source homatropine methylbromide API from specialty API vendors
- and hydrocodone bitartrate from controlled-substance API suppliers under strict compliance terms
- Contract manufacturing organizations (CMOs) typically produce the finished drug at a registered site using customer-supplied APIs.
What distributors act as supply channels for homatropine methylbromide and hydrocodone bitartrate?
For procurement, distributors usually provide:
- verified inventory (COA linked to lot numbers)
- regulatory documentation packages (GMP certificates, vendor declarations)
- logistics controls for controlled opioids
However, distributor lists cannot be stated reliably without an authoritative market-by-market dataset tied to your target country and dosage form.
Which manufacturing routes and quality systems matter for these APIs?
Even when two suppliers are technically “API manufacturers,” differences show up in impurity profiles and analytical controls.
Homatropine methylbromide quality validation typically covers
- stereochemical integrity and identity
- residual solvents and reagents
- related substances and degradation impurities
- particle size and polymorph control where relevant to downstream formulation
Hydrocodone bitartrate quality validation typically covers
- opioid-related impurities
- polymorphic form and crystallinity
- residual solvents per ICH Q3
- controlled-substance chain-of-custody documentation
- calibration and method validation for potency assays
What finished-dose forms are supplied for this combination?
The combination is typically supplied as oral immediate-release solid dosage (for example, tablets) in markets where it is approved.
Supplier selection usually depends on
- formulation technology ownership (blend, granulation, compression)
- coating system compatibility with anticholinergic and opioid stability
- dissolution specifications and bioequivalence requirements
- packaging: child-resistant closures and tamper evidence in opioid-containing products
Which jurisdictions drive supplier selection for these actives?
Supplier capability is constrained by regulatory filing requirements:
- FDA (US) registrations and DMF/ASMF availability
- EMA/NCAs (EU member states)
- UK MHRA
- Canada DPIRS alignment
- other national controlled-substance controls
For opioid-containing combinations, supplier qualification also depends on national controlled-substance import/export permissions.
How do you map suppliers to registrations and DMFs for due diligence?
Procurement teams usually crosswalk:
- Regulatory filing holder (marketing authorization holder)
- Manufacturer of record for API and finished product
- DMF/ASMF holder names tied to the active ingredient
- GMP site addresses and inspection outcomes
- Change control history for route and impurity profile updates
This mapping is the most reliable way to identify the “real” suppliers behind the label.
What Orange Book or comparable listings indicate about supply for this combination?
A robust supplier answer requires tying the combination product to:
- the reference listed drug (RLD) or local equivalent
- patent and exclusivity status
- listed applicants and manufacturers of record
Without an identified target jurisdiction and product strength/form, a precise, audit-ready supplier list cannot be produced.
Key Takeaways
- Homatropine methylbromide is generally supplied by specialty API manufacturers, with quality controls centered on identity, related substances, and degradation profile.
- Hydrocodone bitartrate supply is constrained to licensed opioid API manufacturers with quota, diversion controls, and strict chain-of-custody documentation.
- Combination product supply depends on jurisdiction-specific approvals and controlled-substance regulations, and is usually sourced through a mix of API vendors plus finished-dose manufacturers or CMOs.
- Reliable supplier identification for procurement requires a registration-linked mapping to DMFs/ASMFs and the manufacturer of record for the specific marketed dosage form and strength.
FAQs
- How do I verify the actual API manufacturer behind hydrocodone bitartrate products?
- What documentation package is typically required from hydrocodone bitartrate API suppliers for controlled-substance compliance?
- What quality attributes differ between homatropine methylbromide suppliers that affect formulation performance?
- How do CMOs handle controlled opioid APIs in manufacturing and chain-of-custody processes?
- How does jurisdiction (US vs EU vs Canada) change supplier eligibility for this homatropine and hydrocodone combination?
References (APA)
- ICH. (n.d.). ICH Q3A(R2) and ICH Q3B(R2) (impurities and residual solvents guidance). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
- ICH. (n.d.). ICH Q9, Q10, and Q11 (Quality Risk Management and pharmaceutical development/quality systems). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
